MHRA

#AbbVie #Antibody drug conjugate (ADC) #MHRA #Oncology #Ovarian cancer

Elahere gets UK approval in platinum-resistant ovarian cancer

Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three prior systemic treatment… Read More

#News #Regulatory

Neurons
#Amyotrophic lateral sclerosis (ALS) #Biogen #MHRA #MND #Neuroscience

First new ALS treatment approved in UK in 30 years

Biogen’s Qalsody (tofersen) has been approved in the UK as the first therapy to treat a rare, genetic form of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND).  The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for tofersen through the International Recognition Procedure (IRP)… Read More

#News #Regulatory #Trending News

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

#Gene mutation #Genetic diseases #MHRA #Mitochondria #Rare disease #UCB

TK2d drug gets UK Promising Innovative Medicine designation

Dox – comprising of doxecitine and doxribtimine – to treat thymidine kinase 2 deficiency (TK2d) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA).  TK2d is caused by a genetic mutation in the TK2 gene. This mutation leads to… Read More

#News #Regulatory

Human heart
#Bayer #Cardiovascular disease #Heart failure #MHRA

UK authorises Bayer’s acoramidis for transthyretin amyloidosis

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the use of Beyonttra (acoramidis) in the UK for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).  ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart… Read More

#News #Regulatory

DNA sequencing
#Antibiotics #Bacteria #DNA #Gene sequencing #Infectious diseases #MHRA

DNA sequencing diagnoses bacterial infections faster

Scientists have developed a DNA sequencing approach that can be implemented in hospitals to diagnose bacterial infections faster and more accurately.  Developed by a UK team from Barts Health NHS Trust and the Medicines and Healthcare products Regulatory Agency (MHRA), the service is designed to help doctors… Read More

#Editor's Choice #News

Vaccine research
#Innovate UK #Medical Research Council #MHRA #Regulatory #UK

New UK centres of excellence to accelerate delivery of treatments

Seven new Centres of Excellence for Regulatory Science and Innovation (CERSIs) are to receive funding up to £1 ($1.2) million each, to lead the way in safer, faster pathways for innovative medicines and devices.  The centres will be funded by Innovate UK in partnership with the Medicines… Read More

#News

Bladder
#Bladder cancer #Johnson & Johnson #MHRA #Oncology #Phase III trial

MHRA approves erdafitinib for some urothelial carcinomas

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Balversa (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC). Specifically, the indication covers patients harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received… Read More

#News #Regulatory

Gastric cancer
#Astellas Pharma #Gene mutation #MHRA #Monoclonal antibodies #Oncology

First claudin 18.2 biomarker targeted therapy licensed in Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody. It is licensed in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric… Read More

#News #Regulatory

Heart monitor
#Cardiovascular disease #Heart attack #MHRA #Novo Nordisk #Obesity #Weight loss

MHRA approves semaglutide to reduce risk of cardiovascular events

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke. The GLP-1 receptor agonist is already approved for use in the treatment of obesity and for weight management,… Read More

#News #Regulatory

HIV cell
#Generics #HIV #MHRA #Regulatory

UK regulator approves first generic raltegravir drugs for HIV

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first generic raltegravir drug to treat adult and paediatric HIV patients who weigh at least 40kg. HIV produces an enzyme called HIV integrase which enables multiplication of the virus in cells within the body. Raltegravir stops this enzyme… Read More

#News #Regulatory

Cancer cell
#AstraZeneca #Breast cancer #EU #Gene mutation #MHRA #Oncology

Capivasertib approved for advanced breast cancer in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AstraZeneca’s capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It is approved in cancers that have one or more abnormal PIK3CA, AKT1, or PTEN gene, and does… Read More

#News #Regulatory

Gene therapy
#Asklepios BioPharmaceutical #FDA #Gene therapy #MHRA #Neurodegenerative disorders #Parkinson's

US and UK fast track designations for Parkinson’s gene therapy

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment… Read More

#News #Regulatory

MHRA
#Cell therapy #Clinical trials #Liver disease #Macrophages #MHRA #Resolution Therapeutics

Green light for engineered macrophage cell therapy study 

Resolution Therapeutics has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I/II EMERALD study for its lead candidate RTX001 for patients with decompensated liver cirrhosis.   EMERALD is an open-label, Phase I/II study which will investigate the safety and… Read More

#News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Daiichi Sankyo #MHRA #Oncology

UK approves quizartinib for FLT3-ITD-positive AML

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Daiichi Sankyo's quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults with acute myeloid leukaemia (AML). Each year in the UK around 3,100 people are diagnosed with AML. Julian Beach, MHRA Interim Executive Director, Healthcare… Read More

#News #Regulatory

Stamp of approval
#Blood cancer #GSK #MHRA #Oncology #Rare disease

JAK inhibitor for rare blood cancer approved in Great Britain

GSK’s Omjjara (momelotinib) has been granted marketing authorisation in Great Britain for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. It is approved in patients who are Janus kinase (JAK)… Read More

#News #Regulatory